RU2000131178A - METABOLITES OF ECEINASCIDIN 743 - Google Patents

METABOLITES OF ECEINASCIDIN 743

Info

Publication number
RU2000131178A
RU2000131178A RU2000131178/04A RU2000131178A RU2000131178A RU 2000131178 A RU2000131178 A RU 2000131178A RU 2000131178/04 A RU2000131178/04 A RU 2000131178/04A RU 2000131178 A RU2000131178 A RU 2000131178A RU 2000131178 A RU2000131178 A RU 2000131178A
Authority
RU
Russia
Prior art keywords
etm
administering
patients
patient
treatment
Prior art date
Application number
RU2000131178/04A
Other languages
Russian (ru)
Other versions
RU2225864C2 (en
Inventor
Кеннет Л. РАЙНХАРТ
Хосе Х. МОРАЛЕС
Джоел РЕЙД
Исабель РЕЙМУНДО
Пабло ФЛОРИАНО
ГРАВАЛОС Лола ГАРСИЯ
Original Assignee
Фарма Мар, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарма Мар, С.А. filed Critical Фарма Мар, С.А.
Publication of RU2000131178A publication Critical patent/RU2000131178A/en
Application granted granted Critical
Publication of RU2225864C2 publication Critical patent/RU2225864C2/en

Links

Claims (1)

1. Существенно чистый ЕТМ-305, имеющий следующую структуру
Figure 00000001

2. Существенно чистый ЕТМ-204, имеющий следующую структуру
Figure 00000002

3. Существенно чистый ЕТМ-775, имеющий следующую структуру
Figure 00000003

4. Способ лечения лейкоза млекопитающих в случае необходимости такого лечения у пациентов, включающий в себя введение эффективного количества ЕТМ-305 упомянутому пациенту в единичной дозированной лекарственной форме.1. Substantially pure ETM-305 having the following structure
Figure 00000001

2. Substantially pure ETM-204 having the following structure
Figure 00000002

3. Substantially pure ETM-775 having the following structure
Figure 00000003

4. A method of treating mammalian leukemia, if necessary, such treatment in patients, comprising administering an effective amount of ETM-305 to said patient in a unit dosage form. 5. Способ лечения лейкоза млекопитающих у пациентов при необходимости такого лечения, включающий в себя введение эффективного количества ЕТМ-775 упомянутому пациенту в единичной дозированной лекарственной форме. 5. A method of treating mammalian leukemia in patients, if necessary, such treatment, comprising administering an effective amount of ETM-775 to said patient in a unit dosage form. 6. Способ лечения карциномы легкого млекопитающих у пациентов при необходимости такого лечения, включающий в себя введение эффективного количества ЕТМ-305 упомянутому пациенту в единичной дозированной лекарственной форме. 6. A method for treating mammalian lung carcinoma in patients, if necessary, such treatment, comprising administering an effective amount of ETM-305 to said patient in a unit dosage form. 7. Способ лечения карциномы легкого млекопитающих у пациентов при необходимости такого лечения, включающий в себя введение эффективного количества ЕТМ-775 упомянутому пациенту в единичной дозированной лекарственной форме. 7. A method of treating mammalian lung carcinoma in patients, if necessary, such treatment, comprising administering an effective amount of ETM-775 to said patient in a unit dosage form. 8. Способ лечения аденокарциномы толстой кишки млекопитающих у пациентов при необходимости такого лечения, включающий в себя введение эффективного количества ЕТМ-305 упомянутому пациенту в единичной дозированной лекарственной форме. 8. A method of treating mammalian colon adenocarcinoma in patients, if necessary, such treatment, comprising administering an effective amount of ETM-305 to said patient in a unit dosage form. 9. Способ лечения аденокарциномы толстой кишки млекопитающих у пациентов при необходимости такого лечения, включающий в себя введение эффективного количества ЕТМ-775 упомянутому пациенту в единичной дозированной лекарственной форме. 9. A method of treating mammalian colon adenocarcinoma in patients, if necessary, such treatment, comprising administering an effective amount of ETM-775 to said patient in a unit dosage form. 10. Способ лечения злокачественной меланомы млекопитающих у пациентов при необходимости такого лечения, включающий в себя введение эффективного количества ЕТМ-305 упомянутому пациенту в единичной дозированной лекарственной форме. 10. A method of treating mammalian malignant melanoma in patients, if necessary, such treatment, comprising administering an effective amount of ETM-305 to said patient in a unit dosage form. 11. Способ лечения злокачественной меланомы млекопитающих у пациентов, при необходимости такого лечения, включающий в себя введение эффективного количества ЕТМ-775 упомянутому пациенту в единичной дозированной лекарственной форме. 11. A method of treating mammalian malignant melanoma in patients, if necessary, such treatment, comprising administering an effective amount of ETM-775 to said patient in a unit dosage form. 12. Фармацевтическая композиция, содержащая ЕТМ-305 и фармацевтически приемлемый носитель, разбавитель или наполнитель. 12. A pharmaceutical composition comprising ETM-305 and a pharmaceutically acceptable carrier, diluent or excipient. 13. Фармацевтическая композиция, содержащая ЕТМ-775 и фармацевтически приемлемый носитель, разбавитель или наполнитель. 13. A pharmaceutical composition comprising ETM-775 and a pharmaceutically acceptable carrier, diluent or excipient. 14. Способ изучения метаболизма эктейнасцидина 743 цитохромом CYP3A4 человека, включающий в себя мониторинг тестируемого образца на наличие одного или более метаболитов, выбранных из группы, состоящей из ЕТМ-204, ЕТМ-305 и ЕТМ-775. 14. A method for studying the metabolism of ecteinascidin 743 by human CYP3A4 cytochrome, comprising monitoring a test sample for the presence of one or more metabolites selected from the group consisting of ETM-204, ETM-305 and ETM-775.
RU2000131178/04A 1998-05-11 1999-05-11 Metabolites of ecteinascidine-743, pharmaceutical composition based on their base and methods for treatment RU2225864C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8502498P 1998-05-11 1998-05-11
US60/085,024 1998-05-11

Publications (2)

Publication Number Publication Date
RU2000131178A true RU2000131178A (en) 2003-01-27
RU2225864C2 RU2225864C2 (en) 2004-03-20

Family

ID=22188976

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000131178/04A RU2225864C2 (en) 1998-05-11 1999-05-11 Metabolites of ecteinascidine-743, pharmaceutical composition based on their base and methods for treatment

Country Status (22)

Country Link
US (3) US6316214B1 (en)
EP (1) EP1077698B1 (en)
JP (2) JP4583598B2 (en)
KR (1) KR100643092B1 (en)
CN (3) CN1195514C (en)
AT (1) ATE289810T1 (en)
AU (1) AU759281B2 (en)
BG (1) BG65235B1 (en)
BR (1) BR9910419A (en)
CA (1) CA2331593C (en)
CZ (1) CZ302168B6 (en)
DE (1) DE69923965T2 (en)
ES (1) ES2239442T3 (en)
HU (1) HUP0101960A3 (en)
IL (2) IL139607A0 (en)
NO (1) NO318081B1 (en)
NZ (1) NZ508585A (en)
PL (1) PL192409B1 (en)
RU (1) RU2225864C2 (en)
SK (1) SK285069B6 (en)
TR (1) TR200003470T2 (en)
WO (1) WO1999058125A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4583598B2 (en) * 1998-05-11 2010-11-17 ファルマ・マール・ソシエダード・アノニマ Metabolite of ectenacidin 743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
DK1280809T3 (en) * 2000-04-12 2005-11-07 Pharma Mar Sa Antitumorecteinascidin derivatives
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (en) 2000-05-15 2003-06-06 Pharma Mar Sa Antitumoral analogs of et 743.
CA2447553A1 (en) * 2000-11-03 2002-05-23 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
NZ525730A (en) * 2000-11-06 2004-12-24 Pharma Mar S Compositions for antitumour treatments containing Ecteinascidin 743
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US7407327B2 (en) * 2003-03-21 2008-08-05 Seagate Technology Llc Method and system for withstanding shock in a spindle motor bearing
JP2007511499A (en) 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー combination
PL1658848T3 (en) 2004-10-29 2007-12-31 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
WO2006094012A2 (en) * 2005-03-02 2006-09-08 The Trustees Of Columbia University In The City Of New York Pentacyclic alkaloid compounds and methods of use thereof
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US20090012157A1 (en) * 2006-02-06 2009-01-08 Sears Barry D Sesamol Derivatives as Novel Inhibitors of Arachidonic Acid Formation
TR201903859T4 (en) 2010-11-12 2019-04-22 Pharma Mar Sa Combination therapy with an antitumor antibiotic.
JOP20190254A1 (en) 2017-04-27 2019-10-27 Pharma Mar Sa Antitumoral compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273773A (en) 1979-09-24 1981-06-16 American Home Products Corporation Antihypertensive tricyclic isoindole derivatives
JPS59225189A (en) 1983-06-03 1984-12-18 Shionogi & Co Ltd Quinonamin derivative and its preparation
JPS6084288A (en) 1983-10-13 1985-05-13 Shionogi & Co Ltd Cyanoquinonamine acetate and its production
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
EP0309477B1 (en) 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
DK0574857T3 (en) 1992-06-19 1998-05-04 Hoechst Ag Polycyclic 31668P and 31668U Compounds, Methods for their Preparation and their Use as Antibiotic or Antitumoral Drugs
US5426108A (en) 1993-11-10 1995-06-20 American Cyanamid Company Antibiotic 31F508 ALPHA1, ALPHA2, BETA1 and BETA2
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5809563A (en) * 1996-11-12 1998-09-15 Institute For The Development Of Emerging Architectures, Llc Method and apparatus utilizing a region based page table walk bit
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
IL138856A0 (en) * 1998-04-06 2001-10-31 Univ Illinois Semi-synthetic ecteinascidins
JP4583598B2 (en) * 1998-05-11 2010-11-17 ファルマ・マール・ソシエダード・アノニマ Metabolite of ectenacidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
AU783562B2 (en) 2000-01-19 2005-11-10 Trustees Of Columbia University In The City Of New York, The Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
DK1280809T3 (en) 2000-04-12 2005-11-07 Pharma Mar Sa Antitumorecteinascidin derivatives
MXPA02011319A (en) 2000-05-15 2003-06-06 Pharma Mar Sa Antitumoral analogs of et 743.

Similar Documents

Publication Publication Date Title
RU2000131178A (en) METABOLITES OF ECEINASCIDIN 743
RU2217432C2 (en) Ecteinascidines, pharmaceutical composition containing thereof and method for treatment of tumors
HK1013915A1 (en) Cascade polymer complexes method of manufacture, and pharmaceutical agents containing them
Chaudhry et al. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
ATE262515T1 (en) DISCODERMOLIDE COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS FOR CANCER THERAPY
BRPI0207700B8 (en) mixture of monodisperse conjugates, pharmaceutical composition, and, use of a substantially monodisperse mixture of an insulin polypeptide-oligomer conjugate
RU94022479A (en) Use of antiestrogenic compounds and pharmaceutically acceptable salts and solvents for blood glucose concentration decrease, pharmaceutical preparation
DK0767786T3 (en) 7-Ether Taxol Analogous Antineoplastic Use thereof and Pharmaceutical Preparations Containing These Compounds
ATE102604T1 (en) DIARYL COMPOUNDS AS ANTIATHEROSCLEROTIC AGENTS.
RU2188637C2 (en) Method for applying lamellarine class alcaloids for treating diseases
GEP20053423B (en) Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits
EP2014291A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
ES525920A0 (en) PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF SULFONILUREA, AS WELL AS ITS CORRESPONDING ADDITIONAL SALTS
DE69232554T2 (en) Medicament containing a ligand for the treatment and / or diagnosis of soft tissue tumors
GR3006834T3 (en)
HUP9700661A2 (en) Use of alpha-1-adrenoreceptor antagonists for the production of pharmaceuticals for profilacting and treating cancer
Nakahara et al. Simultaneous malignant melanoma and squamous cell carcinoma of the oral cavity: a case report
MX9702671A (en) Metallocenic diarylethylene derivatives, methods for their preparation and pharmaceutical compositions containing same.
HUP9904578A2 (en) Use of xanomeline for the preparation of pharmaceutical compositions treating bipolar disorder
IT8920465A0 (en) MEDICINAL PREPARATION OF AN EXTRACT OF NETTLE ROOTS, URTICA KIOVENSIS (ROGOWICZ), ITS USE FOR THE TREATMENT OF TUMORS AND PREPARATION PROCESS.
RU95107706A (en) Pyridoindolobenzodiazepines and derivatives thereof, pharmaceutical composition of antipsychotic activity based thereon, and method of medical treatment
ZA200300675B (en) Pharmaceutical preparation of the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma.
TH54857A3 (en) New elements and uses
RU94033096A (en) Compound, method of medical treatment, and pharmaceutical composition